Abstract
Cardiovascular disease remains the leading global cause of death, yet the translation of innovative technologies into clinical practice faces considerable challenges. Academic-industry partnerships offer a collaborative pathway, combining academic clinical expertise with industry resources to systematically advance cardiovascular innovation. These alliances enable the identification of unmet needs, the development and validation of novel solutions, and streamlined regulatory and commercialization processes. Despite their growing importance and the shift in research funding from federal sources to industry collaborations, inconsistent outcomes and ethical concerns persist owing to the lack of standardized partnership frameworks. This review proposes a comprehensive framework to guide successful cardiovascular academic-industry partnerships, emphasizing 5 core principles: strategic alignment, infrastructure investment, systematic assessment, graduated implementation, and robust ethical oversight. Specific partnership types and contractual agreements are discussed, along with common barriers such as divergent priorities and intellectual property conflicts. Through case study analysis and a detailed governance model, we illustrate how dedicated structures and thorough conflict management can foster trust, maximize mutual value, and accelerate patient-centered innovation. Implementing best practices ensures that these partnerships drive global cardiovascular advancements, benefiting academia, industry, and patient outcomes alike.